PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis

BACKGROUND: Inhibitors of programmed cell death 1 (PD-1)/programmed cell death ligand 1(PD-L1) checkpoint have been approved for metastatic triple negative breast cancer (mTNBC) in patients positive for PD-L1 expression. Negative results from the recent phase III trials (IMPassion131 and IMPassion13...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Muhammad, Du, Kunpeng, Ai, Meiling, Wang, Baiyao, Lin, Jie, Ren, Anbang, Chen, Chengcong, Huang, Zhong, Qiu, Wenze, Yuan, Yawei, Tian, Yunhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027008/
https://www.ncbi.nlm.nih.gov/pubmed/36949944
http://dx.doi.org/10.3389/fimmu.2023.1060308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027008/
https://www.ncbi.nlm.nih.gov/pubmed/36949944
http://dx.doi.org/10.3389/fimmu.2023.1060308

Ejemplares similares